Viewing Study NCT01555827


Ignite Creation Date: 2026-03-26 @ 3:21 PM
Ignite Modification Date: 2026-04-14 @ 5:53 PM
Study NCT ID: NCT01555827
Status: COMPLETED
Last Update Posted: 2017-11-13
First Post: 2012-03-14
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Retinal Neurodegenerative Signs in Alzheimer's Diseases
Sponsor: University Hospital, Bordeaux
Organization:

Study Overview

Official Title: Retinal Neurodegenerative Signs in Alzheimer's Diseases
Status: COMPLETED
Status Verified Date: 2017-11
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: SIGNAL
Brief Summary: A few studies suggest that patients suffering from neurodegenerative diseases (such a multiple sclerosis or Alzheimer's disease (AD)) show decreased thickness of the retinal nerve fiber layer (RNFL), indicating axonal degeneration. High-definition spectral domain optical coherence tomography (SD-OCT), performed without radiation in a few seconds per eye, offers a precise and standardized estimation of this parameter, which could constitute a biomarker for cerebral axonal degeneration. These RNFL deficits might even be the earliest sign of AD, prior to damage of the hippocampal region that impacts memory.

Besides, some associations of AD with some degenerative diseases of the eye (glaucoma, microvascular abnormalities, age-related macular degeneration (AMD)) have also been reported.

It therefore seems interesting to determine whether RNFL thickness, and other ocular parameters, may give some indications for a better detection of AD and cognitive decline in the elderly.
Detailed Description: None

Study Oversight

Has Oversight DMC: True
Is a FDA Regulated Drug?: None
Is a FDA Regulated Device?: None
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: